News

Matteo Pellegrino

Recent Posts by Matteo Pellegrino:

AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings

News

(SEATTLE), July 1, 2021 -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, Colorado, currently owned by Novartis Gene Therapies. Once the transaction closes, pending final due diligence, the facility will equip AGC Biologics with significant additional capacity and space to continue to expand its end-to-end Cell and Gene Therapy (C&GT) offering, ensuring security of supply for current and future C&GT customers. This facility is only 16 miles from AGC Biologics’ state-of-the-art large-scale stainless steel mammalian facility in Boulder, CO.dronegenuity-Longmont-CO-017-1

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

News

TEL AVIV, Israel and SEATTLE, Wash. June 21, 2021 – Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA (NASH). Under terms of the agreement, the companies will work together to optimize, upscale and lock the CM-101 manufacturing process towards its testing in pivotal studies while AGC Biologics will manufacture the clinical trial materials at its site in Copenhagen, to support phase II/III clinical testing and launch readiness.
Follow Us
Join us on LinkedIn Follow us on Twitter